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Vascular calcification (VC) is an age-related complica-tion of atherosclerosis, type 2 diabetes mellitus, and 
chronic kidney disease and is characterized by the maladap-
tive transdifferentiation of vascular smooth muscle cells 
(VSMCs) toward an osteochondrogenic lineage, which results 
in hydroxyapatite deposition and eventually mineralization of 
the arterial wall.1,2
Although VC is a risk factor for cardiovascular and all-
cause mortality, a therapy is not yet available, mostly because 
the pathways responsible for the VSMC osteochondrogenic 
phenotypic shift are still poorly understood.3
It has recently emerged that senescence and the acquisi-
tion of an inflammatory senescence-associated secretory phe-
notype increase the propensity of VSMC to experience the 
osteoblastic transition.4,5 Remarkably, senescent VSMCs are 
characterized by the expression of bone-related genes, such as 
Runx2 (Runt-related transcription factor 2), alkaline phospha-
tase, and osteocalcin, and secretion of senescence-associated 
secretory phenotype molecules, such as IL-6 (interleukin 6), 
BMP2 (bone morphogenetic protein 2), and OPG (osteopro-
tegerin), that can induce the senescence and osteoblastic phe-
notype of neighboring VSMCs and local or circulating stem 
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Objective—Vascular calcification (VC) is age dependent and a risk factor for cardiovascular and all-cause mortality. VC 
involves the senescence-induced transdifferentiation of vascular smooth muscle cells (SMCs) toward an osteochondrogenic 
lineage resulting in arterial wall mineralization. miR-34a increases with age in aortas and induces vascular SMC senescence 
through the modulation of its target SIRT1 (sirtuin 1). In this study, we aimed to investigate whether miR-34a regulates VC.
Approach and Results—We found that miR-34a and Runx2 (Runt-related transcription factor 2) expression correlates in young 
and old mice. Mir34a+/+ and Mir34a−/− mice were treated with vitamin D, and calcium quantification revealed that Mir34a 
deficiency reduces soft tissue and aorta medial calcification and the upregulation of the VC Sox9 (SRY [sex-determining 
region Y]-box 9) and Runx2 and the senescence p16 and p21 markers. In this model, miR-34a upregulation was transient 
and preceded aorta mineralization. Mir34a−/− SMCs were less prone to undergo senescence and under osteogenic conditions 
deposited less calcium compared with Mir34a+/+ cells. Furthermore, unlike in Mir34a+/+ SMC, the known VC inhibitors 
SIRT1 and Axl (AXL receptor tyrosine kinase) were only partially downregulated in calcifying Mir34a−/− SMC. Strikingly, 
constitutive miR-34a overexpression to senescence-like levels in human aortic SMCs increased calcium deposition and 
enhanced Axl and SIRT1 decrease during calcification. Notably, we also showed that miR-34a directly decreased Axl 
expression in human aortic SMC, and restoration of its levels partially rescued miR-34a-dependent growth arrest.
Conclusions—miR-34a promotes VC via vascular SMC mineralization by inhibiting cell proliferation and inducing 
senescence through direct Axl and SIRT1 downregulation, respectively. This miRNA could be a good therapeutic target 
for the treatment of VC.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38:2079-2090. 
DOI: 10.1161/ATVBAHA.118.311298.)
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cells.4–9 Accordingly, during aging, the molecular mechanisms 
that favor VSMC senescence, like prelamin A accumulation4 
and ZMPSTE2410 and COMP (cartilage oligomeric matrix 
protein) 11,12 downregulation, promote VSMC osteogenic dif-
ferentiation as well.
miRNAs are negative post-transcriptional regulators of 
gene expression and have potential as therapeutic targets.13 
Although they have been implicated in several cardiovascular 
biological processes, the role of miRNAs in VC is still largely 
unexplored.14 miR-34a was firstly described as a tumor sup-
pressor that can regulate cancer cell proliferation, apoptosis, 
and senescence.15 Notably, miR-34a plays an important role 
during the aging process.16,17 Indeed, its expression increases 
in different aged organs and tissues,6,16,18–20 and its genetic 
ablation or inhibition in mice has been shown to improve 
cardiac performance and ventricular remodeling in the aged 
heart.16 Notably, miR-34a is a senescence-inducer miRNA21 
and can mediate endothelial and endothelial progenitor cell 
senescence through the modulation of its target—the longev-
ity-associated gene SIRT1 (sirtuin 1).18,22 We have recently 
reported that miR-34a is upregulated in aged mouse aortas, 
promoting VSMC senescence through the direct downregu-
lation of SIRT1 and the expression of a subset of senes-
cence-associated secretory phenotype factors, including the 
pro-osteogenic molecules BMP2 and IL-6.6 Interestingly, 
Takemura et al5 have demonstrated that SIRT1 acts as a VC 
inhibitor by counteracting VSMC senescence and their con-
sequent calcification. Notably, miR-34a can regulate other 
VSMC calcification inhibitors, for instance, the antiapoptotic 
receptor tyrosine kinase Axl (AXL receptor tyrosine kinase) 
has been described as a miR-34a target in solid cancer and 
able to inhibit VSMC calcium deposition in vitro.23,24
Given the association among miR-34a, senescence, and 
calcification, we hypothesized that the age-dependent upreg-
ulation of this miRNA may drive the senescence-induced 
VSMC osteochondroblastic changes and thereby VC. We 
found that miR-34a deficiency in vivo reduces soft tissue, 
including aorta, calcification by preventing the expression of 
the VC markers Sox9 (SRY [sex-determining region Y]-box 
9) and Runx2, as well as of the senescence factors p16 and 
p21. Expression of miR-34a increases before aorta mineral-
ization. Smooth muscle cell (SMC) isolated from Mir34a−/− 
mice shows reduced senescence and calcification and slightly 
higher expression of SIRT1 and Axl during the mineraliza-
tion process induced by hyperphosphatemia. Strikingly, miR-
34a–overexressing human aortic SMCs (HASMCs) exhibit 
increased senescence and calcium deposition along with lower 
levels of SIRT1 and Axl. We also demonstrated that miR-34a 
directly targets Axl in HASMC and inhibits their proliferation, 
at least in part, through Axl downregulation.
This study suggests that miR-34a is a promoter of VC, by 
inducing VSMC growth arrest and senescence via direct Axl 
and SIRT1 downregulation, respectively. In the future, a thera-
peutic strategy targeted against miR-34a might be considered 
for the treatment or prevention of age-associated VC.
Materials and Methods
The authors declare that all supporting data are available within the 
article and its online-only Data Supplement.
Animal Experiments
Animal work was performed in conformity with the guidelines from 
Directive 2010/63/EU of the European Parliament on the protec-
tion of animals used for scientific purposes and in accordance with 
experimental protocols approved by the University Committee on 
Animal Resources at the University of Milan (734–2015). Mice were 
housed in standard cages on a 12:12-hour light-dark cycle and fed a 
normal chow diet ad libitum. JAX C57BL/6J mice (Mir34a+/+, wild 
type) were purchased from Charles River Laboratories International, 
Inc. (stock No. 000664; Wilmington, MA). Mir34a−/− mouse line 
was already generated25 and purchased from The Jackson Laboratory 
(stock No. 018279; Bar Harbor, ME).
Only male mice were included in this study because there are 
evidences from the literature showing sex differences as the estro-
gen hormone protects females from VC.26–28 Twelve-week-old male 
Mir34a−/− and Mir34a+/+ were treated with either 500 000 IU·kg−1·d−1 
vitamin D (cholecalciferolor, C1357; Sigma-Aldrich, St. Louis, MO) 
or a mock solution (1% [v/v] ethanol, 7% [v/v] Kolliphor EL, and 
3.75% [wt/vol] dextrose, all from Sigma-Aldrich) administrated 
subcutaneously for 3 consecutive days and euthanized 7 days after 
the first injection.29,30 Animals were anesthetized with an intraperi-
toneal injection of ketamine:medetomidine cocktail (100:10 mg/kg) 
and perfused with PBS from the apex of the heart. Blood was col-
lected by cardiac puncture; aortas, hearts, lungs, and kidneys were 
dissected out and processed for aortic medial thickness and cellu-
lar density measurement, calcium content quantification, von Kossa 
staining, and immunohistochemistry as described in the online-only 
Data Supplement. A semiquantitative calcification score was also 
determined.31 Calcification on arterial cross section at 3 different lev-
els for every mouse was scored using the following system: 0, no 
calcification; 1, focal calcification spots; 2, partial calcification cover-
ing 20% to 80% of the arterial circumference; and 3, circumferential 
calcification.
For the aging experiments, aortas were isolated from C57BL/6J 
male young (2.5 months old) and old (21 months old) mice and 
immediately frozen for RNA and protein extraction or paraffin 
embedded for Alizarin Red staining as described in the online-only 
Data Supplement.
Cell Culture
HASMCs were purchased from Lonza (Basel, Switzerland) and cul-
tured in SmGM-2 complete medium (Lonza). The cell donors were 
white men of 22, 30, and 43 years of age.
Nonstandard Abbreviations and Acronyms
Axl AXL receptor tyrosine kinase
BMP2 bone morphogenetic protein 2
CDK cyclin-dependent kinase
COMP cartilage oligomeric matrix protein
HASMCs human aortic smooth muscle cells
IL-6 interleukin 6
OPG osteoprotegerin
Runx2 Runt-related transcription factor 2
SA-βgal senescence-associated β-galactosidase
SIRT1 sirtuin 1
SMCs smooth muscle cells
Sox9  sex-determining region Y-box 9
SRY sex-determining region Y
VC vascular calcification
VSMCs vascular smooth muscle cells
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Murine SMCs were isolated as already described.32 
Immunofluorescence analyses confirmed that isolated cells express 
α-smooth muscle actin while were not positive for the endothelial 
marker vWF (von Willebrand factor; Figure IIIA and IIIB in the 
online-only Data Supplement).
Cells were transfected and infected as described in the online-
only Data Supplement.
Calcification Assay
Cells were cultured in osteogenic medium (DMEM supplemented with 
15% fetal bovine serum, 5 mmol/L phosphate, 10 mmol/L sodium 
pyruvate, and 50 µg/mL ascorbic acid) for 3 or 7 days. To quantify 
the precipitated calcium, cells grown in 12-well plates were incubated 
overnight with 250 µL of 0.6 N HCl at 4°C, and then, supernatants 
were collected. To extract protein for normalization, cells were incu-
bated overnight at 4°C with 250 µL of 0.1% SDS-0.1 N NaOH lysis 
buffer. The precipitated calcium was quantified by colorimetric analy-
sis with the QuantiChrom Calcium Assay Kit (DICA-500; Gentaur, 
Kampenhout, Belgium), whereas the protein concentration was deter-
mined with the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, 
CA). Cells undergone calcification were also processed for quantitative 
reverse transcriptase polymerase chain reaction and Western blot anal-
yses as described in the online-only Data Supplement.
Statistical Analysis
In vitro experiments were performed at least 3×. Data were analyzed 
with GraphPad Prism software, version 7 (GraphPad Software, Inc, 
La Jolla, CA). The Shapiro-Wilk test was used to assess the normal-
ity of distribution of investigated parameters. Differences between 2 
groups were analyzed with unpaired Student t test or Mann-Whitney 
U test for normally or not normally distributed variables, respec-
tively, otherwise stated in the figure legends. Statistical analysis 
between >2 groups was conducted by 1- or 2-way ANOVA with 
Bonferroni post hoc test, as reported in the figure legends. A value of 
P <0.05 was considered statistically significant; values are presented 
as mean±SE.
Results
Mir34a Genetic Ablation Reduces 
Soft Tissue and VC In Vivo
We have previously demonstrated that miR-34a levels increase 
in the aortas of aged mice along with senescence-associated 
proteins, such as p16 and p21, and that miR-34a induces 
VSMC senescence.6 Old aortas also show signs of calcifica-
tion when compared with young ones (Figure IA and IB in the 
online-only Data Supplement).33,34 Hence, as a prerequisite of 
our study, we correlated the expression of miR-34a and the 
VC marker Runx2 in aortas of young (2.5 months old) and old 
(21 months old) mice. Both miR-34a and Runx2 were upreg-
ulated in aortas of aged animals, with a positive association 
(Figure IC through IE in the online-only Data Supplement). 
Accordingly, Runx2 protein levels increased in old aortas 
(Figure IF in the online-only Data Supplement).
To evaluate whether miR-34a could play a role in VC, 
Mir34a+/+ and Mir34a−/− mice were subcutaneously injected 
for 3 consecutive days with a toxic dose of vitamin D or a 
mock solution (control [Ctrl]) and euthanized 7 days after the 
first injection.29,30 Although Mir34a+/+ and Mir34a−/− animals 
showed a slightly different body weight before the treatment 
(Figure IIA in the online-only Data Supplement), weight loss 
on vitamin D treatment was significantly lower in Mir34a−/− 
than in Mir34a+/+ mice, indicating a major discomfort in the 
latter group (Figure 1A). As expected, calcium levels increased 
in the sera of vitamin D-treated mice when compared with 
the corresponding control group; interestingly, serum calcium 
in vitamin D-treated Mir34a−/− animals was lower than those 
in corresponding Mir34a+/+ mice (Figure 1B). We quantified 
calcium deposition in soft tissues, including kidneys, lungs, 
hearts, and aortas. Whereas calcium deposition was negligible 
in control mice, it significantly raised in vitamin D-treated 
mice; notably, the genetic ablation of Mir34a reduced calcifi-
cation in all tested organs (Figure 1C).
To investigate VC, we further characterized aortas of these 
animals. Aortas of Mir34a−/− mice showed a basal higher 
medial thickness and cellular density than Mir34a+/+ (Figure 
IIB through IID in the online-only Data Supplement). Then, 
we assessed calcium deposition by von Kossa staining on 
aortic sections. In comparison with Mir34a+/+ animals, fewer 
Mir34a−/− mice accumulated calcium in the medial arterial 
layer and to a lesser extent after vitamin D administration 
(Figure 2A through 2C). We also analyzed by immunohisto-
chemistry the expression pattern of 2 well-known VC makers, 
Runx2 and Sox9,2,31 as well as of p16 and p21; we observed 
that only Mir34a+/+ mice displayed positive staining in VSMC 
nearby the calcified regions (Figure 2D).
Altogether, our data demonstrate that Mir34a deficiency 
reduces soft tissue and VC induced by an overdose of vitamin 
D in vivo. In the aorta, Mir34a deficiency prevented senes-
cence and transdifferentiation of VSMC.
miR-34a Is Upregulated in Aortas That Display 
Features of Senescence Before Overt Calcification
To gain further insight in the role of miR-34a in VC, we deter-
mined its expression in aortas and serum of wild-type mice 
during the mineralization process induced by vitamin D. In 
the aorta, calcium deposition was detectable at day 5 and was 
significantly higher at day 7 after the first injection of vita-
min D in comparison with the corresponding mice treated 
with mock solution (Ctrl; Figure 3A). Notably, an induction 
of miR-34a by vitamin D was already evident at day 3 but 
soon decreased to the levels of Ctrl at day 5 (Figure 3B). 
Interestingly, p21 mRNA was markedly upregulated at days 
3 and 5 (Figure 3C). No significant differences in circulating 
miR-34a levels were detected between vitamin D-treated and 
Ctrl mice at any time point, although a trend to a decrease in 
its amount was observed during the progression of calcifica-
tion (Figure 3D).
These results indicate that in vivo vitamin D treatment 
induces a transient upregulation of miR-34a that is concomi-
tant with p21 induction and precedes overt aortic calcification.
Mir34a Genetic Ablation Decreases SMC 
Senescence and Calcium Deposition Ex Vivo
To better investigate the possible role of miR-34a in the 
SMC osteochondrogenic transition, we isolated SMC from 
Mir34a+/+ and Mir34a−/− mice (Figure IIIA and IIIB in the 
online-only Data Supplement). In accordance with our pre-
viously published data6 and aorta cell density data (Figure 
IIB and IID in the online-only Data Supplement), Mir34a−/− 
cells displayed a higher proliferation rate than Mir34a+/+ 
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furthermore, they showed lower SA-βgal (senescence-asso-
ciated β-galactosidase) activity and p16 expression, when 
compared with Mir34a+/+ cells (Figure IIID and IIIE in the 
online-only Data Supplement). We induced Mir34a+/+ and 
Mir34a−/− SMC calcification by culturing them for 7 days in 
an osteogenic medium containing a pathological concentra-
tion of inorganic phosphate. In accordance with our in vivo 
results, Mir34a−/− SMCs deposited lower levels of calcium 
relative to Mir34a+/+ cells (Figure 4A).
To get deeper insight in the molecular pathways affected 
by miR-34a that promote SMC calcification, we evaluated the 
expression of the VC inhibitors Axl and SIRT1.5,23 We have 
previously demonstrated that miR-34a directly targets SIRT1 
and promotes senescence in HASMC,6 whereas Axl is known 
to be targeted by miR-34a in other cell types.24 Interestingly, 
during SMC mineralization, Axl mRNA level was higher 
in Mir34a−/− SMCs in respect to Mir34a+/+ cells at day 3 
(Figure 4B), whereas SIRT1 mRNA expression was not sig-
nificantly increased (Figure 4C). At day 7, both transcripts 
were not influenced by the absence of Mir34a (Figure 4B 
and 4C). Both SIRT1 and Axl proteins were downregulated in 
Mir34a+/+ cells at day 7 when compared with day 3, whereas 
they were not or less modulated in Mir34a−/− SMCs, respec-
tively (Figure 4D through 4F).
These results demonstrate that SMCs lacking miR-34a 
expression have higher proliferation rate, reduced propensity 
to undergo senescence and deposit calcium, and show higher 




Figure 1. Mir34a genetic ablation reduces soft tissue calcification. A–C, Twelve-week-old Mir34a−/− and Mir34a+/+ mice were treated subcutaneously with 
either vitamin D (vit D) or a mock solution (control [Ctrl]) for 3 consecutive days and euthanized 7 d (day 7) after the first injection. A, Mice weight ratio at the 
third day (day 3) and before the first vit D injection (day 1; n=6, 5, 13, and 8). B, Calcium content in the sera at day 7 was quantified by a colorimetric analy-
sis (n=9, 8, 17, and 11). C, Calcium content in the indicated organs and tissue was quantified by the colorimetric analysis (n=6, 5, 12–13, and 8). Values are 
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miR-34a Inhibits VSMC Proliferation by 
Directly Targeting Axl in HASMC
Next, we verified whether miR-34a can specifically modu-
late Axl in VSMC. We transfected HASMC with a miR-34a 
mimic or a mimic negative control; miR-34a overexpres-
sion downregulates Axl protein levels already at 24 hours 
post-transfection (Figure 5A). Accordingly, Axl expression 
was higher in HASMC transfected with a miR-34a inhibitor 
compared with the scramble (SCR) control (Figure 5B). To 
prove that miR-34a directly affects Axl expression, we trans-
fected HASMCs with a vector carrying Axl cDNA devoid of 
the 3′-UTR (untranslated region) containing miR-34a seed 
sequence24 or an empty vector, together with a miR-34a 
mimic or a mimic negative control. Western blot analysis 
confirmed that the endogenous Axl was severely lowered 
upon miR-34a overexpression, whereas the exogenous Axl 
was unaffected by miR-34a ectopic expression (Figure 5C). 
Because Axl regulates cell proliferation and survival,35 we 
determined whether its downregulation mediated by miR-34a 
could affect HASMC growth. As expected, miR-34a reduced 
cell number 72 hours after transfection (empty miR-34a ver-
sus empty SCR; Figure 5D); Axl ectopic expression alone 
increased the number of HASMC (Axl SCR versus empty 
SCR; Figure 5D) and, in combination with miR-34a, partially 
Figure 2. Mir34a genetic ablation reduces vascular calcification. A, Representative images of von Kossa staining (black) on sections from distal thoracic aor-
tas. Nuclei were counterstained with hematoxylin (purple; scale bar=100 μm). B, Bars show the percentage of von Kossa-positive area to the total aortic area 
of vitamin D (Vit D)-treated mice (n=13 and 7). Values are mean±SE. Mann-Whitney U test. **P<0.01. C, Evaluation of vascular calcification by a semiquantita-
tive scoring of von Kossa-stained aortic sections of vit D-treated and (control [Ctrl]) mice. D, Enlarged images of the von Kossa-stained sections shown in A 
and adjacent sections stained with antibodies specific for the indicated proteins or nothing (negative control [NC]) of vit D-treated mice (brown, black arrows; 
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reversed miR-34a–mediated inhibition of cell proliferation 
(Axl miR-34a versus empty miR-34a; Figure 5D).
All together, these data indicate that miR-34a inhibits 
VSMC proliferation to some extent through the direct modu-
lation of Axl.
miR-34a–Induced Senescence Enhances 
HASMC Calcification Through Axl 
and SIRT1 Downregulation
We previously demonstrated that proliferative/young 
HASMCs express lower miR-34a levels compared with old/
senescent HASMC, and transient miR-34a overexpression 
in young cells induces senescence.6 Because old/senescent 
HASMC calcify more compared with young cells,5,36 we veri-
fied whether miR-34a–induced VSMC senescence enhances 
VC. First, we set up an in vitro model of proliferative/young 
HASMC calcification induced by hyperphosphatemia. A sig-
nificant augmentation of calcium deposition was observed 
by von Kossa staining and colorimetric analysis (Figure IVA 
and IVB in the online-only Data Supplement) along with an 
upregulation of VC markers alkaline phosphatase and Runx2 
during the calcification process (Figure IVC through IVE in 
the online-only Data Supplement).
Then, we confirmed in our experimental conditions 
that senescent HASMC (passage 15) expressing higher lev-
els of miR-34a mineralize more than young cells (passage 
5; Figure 6A). Thus, we used a lentiviral infection to stably 
express miR-34a in proliferative HASMC to a level com-
parable with senescent HASMC (Figure VA in the online-
only Data Supplement). Indeed, miR-34a-overexpressing 
HASMCs had greater SA-βgal activity, increased or decreased 
levels of the growth arrest marker p21 or Axl and SIRT1 
mRNA, respectively (Figure VB through VE in the online-
only Data Supplement). Strikingly, miR-34a-overexpressing 
HASMCs evidenced a rise in calcium deposition at day 7 of 
calcification, which was not seen in scramble control cells 
(SCR; Figure 6B).
Hence, we assessed Axl and SIRT1 expression during the 
mineralization process. Axl mRNA levels were lower in miR-
34a–overexpressing HASMC at both days 3 and 7 in respect 
to SCR cells, whereas no major differences were detected for 
the SIRT1 transcript (Figure 6C and 6D). Western blot analy-
sis revealed that both proteins decreased significantly at day 
3 of calcification in miR-34a–overexpressing cells compared 
with control SCR HASMC (Figure 6E through 6G).
Finally, we determined miR-34a expression in HASMC 
at different days of culture in the osteogenic medium observ-
ing no significant modulation of its levels during the osteo-
chondrogenic transition (Figure VI in the online-only Data 
Supplement).
Taken together, our findings show that miR-34a upregu-





Figure 3. miR-34a is upregulated in aortas of vitamin D (vit D)-treated mice that display features of senescence before overt calcification. Twelve-week-old 
wild-type mice were treated subcutaneously with either vit D or a mock solution (control [Ctrl]) for 3 consecutive days and euthanized 3 (day 3), 5 (day 5), 
or 7 (day 7) d after the first injection. A, Calcium content in the aortas was quantified by colorimetric analysis (n=5, 5, 5, 5, 3, and 5). B and C, miR-34a and 
p21 expression in the aortas was analyzed by quantitative reverse transcriptase polymerase chain reaction and normalized to corresponding U6 and Hprt 
levels, respectively (n=5, 5-3, 5, 5-4, 3, and 5). D, miR-34a levels in the sera of mice were determined at the indicated days (n=5, 4, 5, 5, 3, and 5). Values are 
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senescence to promote calcification through downregulation 
of its targets Axl and SIRT1.
Discussion
VC is a pathology that occurs frequently in the elderly popu-
lation and is associated with atherosclerosis, type 2 diabetes 
mellitus, and chronic kidney disease, which are diseases dis-
playing features of premature aging.8,37,38 Although the sub-
jects with VC are high-risk patients, an effective therapy is 
not yet available because of the poor understanding of the 
molecular mechanisms underlying this complication.3
We recently published that miR-34a is upregulated in 
aged murine aortas and that an increase of its levels in VSMC 
induces growth arrest, senescence, and the expression of 
certain senescence-associated secretory phenotype factors, 
including the pro-osteogenic molecules BMP2 and IL-6.6 In 
the present study, we demonstrated for the first time that the 
aging-associated miR-34a is a VC promoter.
We confirmed previous data reporting that aortas of aged 
mice show signs of calcification along with increased expres-
sion of VC markers, such as Runx2 (Figure IA, IB, ID, and IF 
in the online-only Data Supplement).33,34 Using an established 
mouse model of soft tissue and aortic medial layer calcifica-
tion induced by an overdose of vitamin D,29,30 we demonstrated 
that Mir34a gene deletion prevents VC in vivo. miR-34a defi-
ciency significantly reduced calcium levels in the serum and all 
tested organs and, with particular regard to aortas, prevented 
the induction of Runx2 and Sox9 and aortic VSMC osteocon-
drogenic transdifferentiation (Figures 1 and 2). Expression of 






Figure 4. Mir34a genetic ablation significantly decreases smooth muscle cell (SMC) senescence and calcium deposition in vitro. A–F, SMCs were isolated 
from Mir34a−/− and Mir34a+/+ mice. A, Cells were cultured in the osteogenic medium for 7 d, and the amount of precipitated calcium was quantified by colo-
rimetric analysis (n=7). Relative calcium levels of Mir34a−/− to corresponding Mir34a+/+ SMC were shown. Values are mean±SE. **P<0.01. Paired t test. B–F, 
Cells were cultured in the osteogenic medium for 3 or 7 d (days 3 and 7). B and C, Axl (AXL receptor tyrosine kinase) and SIRT1 (sirtuin 1) mRNA levels 
were analyzed by quantitative reverse transcriptase polymerase chain reaction and normalized to corresponding Hprt levels (n=3, 3, 4, and 3). D–F, Protein 
extracts were subjected to Western blot analysis with anti-Axl, anti-SIRT1, or anti–α-tubulin (loading control) antibodies. E and F, Bars show quantification of 
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aortas of Mir34a+/+ mice (Figure 2D) that is in line with previ-
ously published data showing that these 2 senescence markers 
are upregulated in calcified rodent aortas, human arteries, and 
VSMCs.4,5,39–42 Notably, after vitamin D treatment, miR-34a 
levels raised in a transient manner before a detectable amount 
of calcium was deposited in the aorta and along with p21 
induction (Figure 3A through 3C) suggesting that in vivo miR-
34a upregulation is necessary to promote tissue senescence 
Figure 5. Axl (AXL receptor tyrosine kinase) expression is directly modulated by miR-34a in human aortic smooth muscle cells (HASMC). A, HASMC were 
transfected with a miR-34a mimic (miR-34a) or a mimic control (scramble, SCR) and cultured for 24 or 48 h. Protein extracts were analyzed with anti-Axl or 
anti-GAPDH (loading control) antibody (left). Bars show quantification of normalized densitometric ratios (n=4 and 5; right). B, HASMCs were transfected 
with a miR-34a hairpin inhibitor (anti-miR-34a) or a hairpin inhibitor negative control (SCR) and cultured for 72 h. Protein extracts were analyzed with anti-Axl 
or anti-GAPDH (loading control) antibody (left). Bars show normalized densitometric ratios (n=4; right). C and D, HASMCs were transfected with miR-34a or 
SCR along with either a 3ʹ untranslated region-deleted Axl-expression vector (Axl-Δ3′UTR) or an empty vector (empty). C, Twenty-four hours after transfec-
tion, protein extracts were analyzed with anti-Axl or anti-GAPDH (loading control) antibody (left). Bars show quantification of normalized densitometric ratios 
(n=3; right). D, The graph shows the cell number at 72 h after transfection (n=5). Values are mean±SE. Student t test or 1-way ANOVA with Bonferroni post 
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that eventually triggers the onset and progression of calcifica-
tion. In accordance, it has been shown that the activation of 
the senescence program by a calcification stimulus precedes 
and controls VSMC mineralization process,43 and senescence 
still occurs when osteogenesis is blocked by silencing specific 
calcification factors like Runx2.10
Our in vitro data support the in vivo findings. Senescent 
VSMCs that express higher amount of miR-34a are more 
prone to calcify in response to high phosphate compared with 
younger cells (Figure 6A)5,6,36 and miR-34a–induced senes-
cence facilitates calcification mediated by hyperphosphate-






Figure 6. miR-34a overexpression increases human aortic smooth muscle cell (HASMC) calcium deposition. A, Calcium deposition quantification with the 
colorimetric analysis at 3 and 7 d of culturing in osteogenic medium of HASMC at a proliferative passage (P5) and at senescence (passage 15 [P15]). B–G, 
HASMCs were infected with either pMIRNA1 (SCR) or pMIRH34a (miR-34a) lentivirus at an MOI (multiplicity of infection) of 10 and cultured in growth medium 
for 48 h. Then, they were cultured in the osteogenic medium for 3 (day 3) or 7 (day 7) d. B, The amount of precipitated calcium was quantified by colorimetric 
analysis (n=7). C and D, Axl (AXL receptor tyrosine kinase) and SIRT1 (sirtuin 1) mRNA levels were analyzed by quantitative reverse transcriptase polymerase 
chain reaction and normalized to corresponding GAPDH levels (n=3). E, Protein extracts were analyzed with anti-Axl, anti-SIRT1, or anti-GAPDH (loading 
control) antibody. F and G, Bars show quantification of normalized densitometric ratios (n=3). Values are mean±SE. One-way ANOVA with Bonferroni post 
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senescence features, as revealed by lower SA-βgal staining 
signal and p16 expression, and reduced calcium deposition 
when compared with Mir34a+/+ cells (Figure IIID and IIIE 
in the online-only Data Supplement; Figure 4A); conversely, 
constitutive overexpression of miR-34a to senescence-like lev-
els in HASMC enhanced calcification (Figure VA through VC 
in the online-only Data Supplement; Figure 6B). Furthermore, 
miR-34a is not modulated during HASMC mineralization 
(Figure VI in the online-only Data Supplement). Hence, miR-
34a being an inducer of VSMC growth arrest and senescence 
is involved in the early mechanisms indispensable for VSMC 
osteochondrogenic transdifferentiation.
Interestingly, our in vitro experiments showed milder 
effects of miR-34a on SMC calcification compared with the in 
vivo results. The difference may depend on the contribution of 
other cell types to VC. In fact, it has been shown that pericytes, 
endothelial cells, fibroblasts, and resident and circulating pro-
genitor cells can differentiate toward an osteochondrogenic 
lineage as well and thereby participate to the calcification 
process.44 Hence, the low propensity to VC of Mir34a−/− mice 
could be explained by the prevention of the osteochondrogenic 
transition of other cell types in addition to SMC.
Mechanistically, we identified 2 VC inhibitors, SIRT1 and 
Axl,5,23 as miR-34a targets during the calcification process. It 
has been already shown that SMC osteoblastic transdifferenti-
ation is characterized by SIRT1 downregulation, and maintain-
ing of high levels of this protein prevents SMC calcification 
through senescence inhibition.5 We have already proven that 
SIRT1 is a direct miR-34a target in HASMC and that its miR-
34a–mediated downregulation enhances senescence in these 
cells.6 In this study, we further show that the direct modula-
tion of SIRT1 by miR-34a influences calcification of VSMC. 
In fact, unlike wild-type murine SMCs, SIRT1 protein levels 
were not significantly altered in Mir34a−/− cells under high 
phosphate conditions (Figure 4D and 4F), whereas they were 
significantly reduced at an early stage of calcification in miR-
34a–overexpressing HASMCs (Figure 6E and 6G). A similar 
behavior was found for Axl (Figures 4D, 4E, 6E, and 6F).
Cells must arrest their cell cycle before undergoing senes-
cence.40 miR-34a inhibits HASMC proliferation by blocking 
the G1- to S-phase transition along with the upregulation of 
p21 protein levels before SIRT1 downregulation.6 Herein, we 
demonstrated that Mir34a−/− aortas display a higher VSMC 
density and isolated Mir34a−/− SMC, an enhanced proliferative 
rate (Figures IIB through IID and IIIC in the online-only Data 
Supplement) further corroborating miR-34a as an important 
regulator of VSMC proliferation. Furthermore, we validated 
Axl as a miR-34a target in HASMC and found that miR-34a 
downregulates Axl with a faster kinetic compared with SIRT1 
(24 versus 48 hours) and alongside with p21 upregulation and 
cell cycle arrest (Figure 5A through 5C).6 Axl signaling has 
been shown to control several VSMC functions including pro-
liferation,45 migration,46 and cell survival47; furthermore, Axl is 
also known to be downregulated during cell mineralization and 
its overexpression inhibits VSMC calcification via activation of 
the antiapoptotic PI3K (phosphatidylinositol 4,5-bisphosphate 
3-kinase)/AKT (RAC-alpha serine/threonine-protein kinase) 
pathway.23 Our findings demonstrate that miR-34a, at least in 
part, inhibits HASMC proliferation by directly reducing Axl 
protein levels (Figure 5C and 5D) and that under a procalcifi-
cation stimulus, miR-34a–dependent Axl decrease favors SMC 
osteocondrogenic transition (Figures 4D, 4E, 6E, and 6F). The 
mild effect of Axl modulation on HASMC proliferation is 
likely because miR-34a is known to influence cell growth by 
targeting also several regulators of the cell cycle machinery, 
such as CDKs (cyclin-dependent kinases) and cyclins.48–51
At the molecular level, miRNAs bind mRNA targets to 
mediate RNA degradation or inhibit protein translation.52 We 
found that both Axl and Sirt1 mRNAs diminish in HASMC 
soon after miR-34a overexpression, nevertheless, the effect on 
Axl mRNA levels is much greater (Figure VD and VE in the 
online-only Data Supplement) indicating 2 different mecha-
nisms of regulation. It has been demonstrated that miR-34a does 
not completely degrade SIRT1 transcript but interferes mainly 
with its translation.53,54 In line with published evidences, dur-
ing SMC and HASMC calcification, miR-34a decreases SIRT1 
protein expression mainly by interfering with the translation of 
its transcript (Figures 4C, 4D, 4F, 6D, 6E, and 6G). On the con-
trary, miR-34a affects Axl protein expression by inducing deg-
radation of the mRNA (Figures 4B, 4D, 4E, 6C, 6E, and 6F).
Taken together, our data suggest that miR-34a may pro-
mote VC by influencing proliferation and senescence of 
VSMC through different pathways; first, it inhibits cell 
growth partially via Axl downregulation and then enhances 
senescence by inhibiting SIRT1. Both events ultimately lead 
to VSMC osteochondrogenic transition (Graphic Abstract). 
Other miR-34a targets are likely to be involved in the calcifi-
cation process: for instance, it has been reported that miR-34a 
can inhibit SMC proliferation via Notch1.55
A limitation of the present study is that soft tissue calcifi-
cation has been induced in young animals. Future works must 
include aged Mir34a−/− and Mir34a+/+ mice.
Altogether, the present study pinpoints miR-34a inhibition 
as a promising therapeutic approach for the treatment of age-
related cardiovascular diseases.
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Highlights
• miR-34a genetic ablation reduces soft tissue and vascular calcification.
• miR-34a promotes vascular smooth muscle cell calcification by inducing cell growth arrest and senescence.
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